Trial Profile

A phase I trial of IMP701 LAG03 antibody for the treatment of cancer

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMP 701 (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

29 Mar 2018 According to an Immutep Limited media release, GSK could extend the study to additional indications including rheumatoid arthritis and multiple sclerosis subjects to evidence of efficacy.
28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
18 Aug 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com